Full Press Release Details
DURHAM, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel, CFO, will participate in the Wells Fargo Healthcare Conference. Management’s presentation will take place on Wednesday, September 3rd, 2025 at 1:30 p.m. E.T.
For one-on-one meeting requests please contact your institutional sales representative. A webcast of the presentation will be available on the Events and Presentations pages of Pelthos’ website athttps://pelthos.com. Archived replays will be available for 90 days following the event.
About Pelthos TherapeuticsPelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment ofmolluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available atwww.pelthos.com. Follow Pelthos onLinkedInandX.